Edition:
United Kingdom

Nordic Nanovector ASA (NANOV.OL)

NANOV.OL on Oslo Stock Exchange

81.05NOK
3:25pm GMT
Change (% chg)

kr-4.40 (-5.15%)
Prev Close
kr85.45
Open
kr77.00
Day's High
kr82.30
Day's Low
kr76.20
Volume
1,027,842
Avg. Vol
215,532
52-wk High
kr113.00
52-wk Low
kr66.40

Summary

Name Age Since Current Position

Ludvik Sandnes

2014 Independent Chairman of the Board

Luigi Costa

52 2014 Chief Executive Officer

Tone Kvale

48 Chief Financial Officer

Jan Alfheim

2014 Chief Operating Officer

Jostein Dahle

Chief Scientific Officer

Anniken Hagen

Chief Quality Officer

Marco Renoldi

2014 Chief Business Officer

Lisa Rojkjaer

2016 Chief Medical Officer

Reza Safaei

2017 Head of Medical Affairs

Jean-Pierre Bizzari

62 2016 Director

Per Samuelsson

56 2014 Director

Gisela Schwab

60 2015 Director

Joanna Horobin

61 2016 Non-Executive Director

Hilde Hermansen Steineger

50 2014 Independent Director

Biographies

Name Description

Ludvik Sandnes

Mr. Ludvik Sandnes has been Independent Chairman of the Board of Directors of Nordic Nanovector ASA since November 12, 2014. He has served as Member of the Board of Directors of the Company since June 2013. He is Member of the Audit and Remuneration Committees. He has over 40 years of experience from international corporate finance, asset management and investment banking from Norfund, The Royal Bank of Scotland, BDO Noraudit, PwC Financial Advisors, Christiania Bank, UNI Storebrand, Orkla Borregaard, Den Norske Credtibank and Statoil. He has a Bachelor of Commerce and is a Certified European Financial Analyst (AFA) from the Norwegian School of Economics and Business Administration, NHH.

Luigi Costa

Mr. Luigi Costa has served as Chief Executive Officer of Nordic Nanovector ASA since September 1, 2014. He has more than 20 years of experience in the international pharmaceuticals and biotech industry. Previously, he held the position of vice president of Europe, Middle East and Africa for Onyx Pharmaceuticals, a global biopharmaceutical company based in San Francisco, California. Mr. Costa was responsible for the startup of the company’s international organization and for the prelaunch and launch of its hematology drug, Kyprolis, in over fifty countries outside the USA. Prior to joining Onyc Pharmaceuticals, he spent eight years with Amgen holding leading management positions including head of International Oncology Franchise and general manager of Italy and France. He has also held various positions with Eli Lilly. He holds a Bachelor of Science in Business Administration from the University of Parma and an MBA from SDA Bocconi in Milan.

Tone Kvale

Mrs. Tone Kvale serves as Chief Financial Officer (CFO) at Nordic Nanovector AS. She has been employed at the Company since November 2012. She has 18 years of experience from the biotech industry. Prior to joining Nordic Nanovector, she was employed as CFO in NorDiag ASA. In addition, she has held senior management positions at Kavli Holding AS, Invitrogen/Life Technologies, United States and Dynal Biotech AS. She has a diploma in Finance & Administration from Harstad University College (1990).

Jan Alfheim

Mr. Jan A. Alfheim has served as served as Chief Operating Officer at NORDIC NANOVECTOR ASA since September 1, 2014. He was Chief Executive Officer (CEO) of Nordic Nanovector ASA from August 2011 until September 1, 2014. He has 30 years of experience in the healthcare and chemical industries. Before joining Nordic Nanovector, he worked for the Norwegian cancer drug development company, Clavis Pharma ASA, as Chief Business Officer and Member of the Senior Management Team. Prior to joining Clavis, he spent seven years in Canada, first as Director of Business Development at Neurochem Inc and as President of Stempath Inc. He holds a Master of Science degree in Chemistry from Concordia University from 1985 and a Master of Business Administration degree from McGill University in Montreal from 2002.

Jostein Dahle

Dr. Jostein Dahle, Ph.D. serves as Chief Scientific Officer (CSO) of Nordic Nanovector AS. He has been employed at the Company since January 2011. He has over 15 years of experience in cancer research. He comes from the position of Leader of the Radioimmunotherapy group at the Institute for Cancer Research at the Norwegian Radium Hospital. He holds a Doctorate of Philosophy degree in radiation biology from the University of Oslo from 2000 and a Master of Science degree in biophysics from the Norwegian University for Science and Technology in Trondheim from 1995. He is one of the Inventors of Betalutin, and has published over 40 papers in the field of cancer and biotechnology.

Anniken Hagen

Mrs. Anniken Hagen serves as Chief Quality Officer at Nordic Nanovector AS. She joined the Company in August 2012. She has over 25 years of experience in the pharmaceutical industry and 10 years within radiopharmacy. In her previous position, she was Head of QA responsible for building facilities and QMS for GMP manufacturing of positron emission radiopharmaceuticals (PET) at Oslo University Hospital. Previously, she worked for Algeta ASA as Quality Control (QC) Manager and was also a part of the team compiling documentation for regulatory applications, including IND applications. From a prior employer, Pronova Biomedical AS, she also has experience in drug delivery systems for among others, anticancer therapeutics. She is trained Chemist and earned a Master’s degree in Radiochemistry from the University of Oslo.

Marco Renoldi

Mr. Marco G. Renoldi, M.D. has been Chief Business Officer at NORDIC NANOVECTOR ASA since November 3, 2014. Prior to joining Nordic Nanovector, Mr. Renoldi served as SVP & Chief Commercial Officer at Shionogi Ltd., from July 2012 to October 2014. From January 2009 to June 2012 he served as Executive Director & International Franchise Head, Oncology-Hematology at Amgen, where he had previously led the Italian affiliate as Managing Director. Prior to joining Amgen, Mr. Renoldi held national, regional and global R&D and business roles at Novartis, Searle-Monsanto and Pharmacia. In his 28-year industry experience Mr. Renoldi has developed product lines and businesses, including start-ups. Mr. Renoldi holds a medical degree from the University of Milan and an MBA from Fondazione IDI/Assolombarda.

Lisa Rojkjaer

Dr. Lisa Rojkjaer has served as Chief Medical Officer of Nordic Nanovector ASA since November 15, 2016. She is a board-certified haematologist with more than 15 years of global and regional clinical development and medical affairs expertise in the biotech and pharma industries, and has extensive experience in the development of both biologics and small molecules in haematology and immunology. She joins Nordic Nanovector from Novartis Pharmaceuticals where she held the position of Global Clinical Program Head, Oncology Global Development. Her previous roles also include CMO at Molecular Partners (Switzerland), Vice President, Head of Clinical Development at Morphosys AG (Germany), and Head of Global Medical Affairs, Biopharmaceuticals and Director of Clinical Development, Hematology in the US for Novo Nordisk. Dr. Rojkjaer holds a medical degree from the University of Toronto and received board certification in both internal medicine and hematology

Reza Safaei

Dr. Reza Safaei, M.D. has been Head of Medical Affairs at Nordic Nanovector ASA since August 2, 2017. Dr. Safaei brings extensive experience in the development and commercialization of novel therapeutics for hematological and solid cancers, gained with several world-leading biopharmaceutical companies. In his most recent role, Dr. Safaei held the position of Head of Medical Affairs Europe at Seattle Genetics, where he managed medical affairs and clinical development activities of pipeline products in acute myeloid leukemia and diffuse large B cell lymphoma (DLBCL), bladder cancer and advanced breast cancer. Prior to this, Dr. Safaei served as Director, Medical Development, Immuno-Oncology and Scientific Communications, Hematology at AMGEN Europe. Dr. Safaei is trained in Internal Medicine and holds a Medical Degree from the University of Goettingen, Germany.

Jean-Pierre Bizzari

Dr. Jean-Pierre Bizzari, M.D. has been Director of NORDIC NANOVECTOR ASA since May 19, 2016. Jean-Pierre Bizzari has significant industry experience from leadership positions in oncology with highly reputable companies as Celgene, Rhone-Poulenc and Sanofi-Aventis, where he was involved in the clinical development of several anticancer products, including Taxotere, Eloxatin, Revlimid, Vidaza, Abraxane and Irinotecan. He is a world-renowned oncology expert, member of the Scientific Advisory Board of the French National Cancer Institute and European Organization of Research and Treatment of Cancer and Chairman of the New Drug Advisory Committee. He is also an active board member in various biotech companies in France and the USA. Dr. Bizzari holds a medical degree with specialization in oncology from the University of Nice (France) completed with training at the Pitie-Salpetriere hospital in Paris, the Ontario Cancer Institute and at the Montreal Mac Gill Cancer Center in Canada.

Per Samuelsson

Mr. Per Samuelsson has been Director of NORDIC NANOVECTOR ASA since November 12, 2014. He is Member of Audit Committee and Chairman of Remuneration Committee of the Company. Per Samuelsson is a partner at Odlander Fredrikson/HealthCap, the life sciences venture capital firm, which he joined in 2000. Prior to this, he gained more than 15 years of investment banking experience, mainly with Aros Securities in Sweden. In his final position with Aros Securities, as a Director in the firm’s corporate finance department, he specialized in the areas of merger transactions, initial public offerings, and equity incentive programs. Prior to this, Mr. Samuelsson was Head of Research, also at Aros Securities. Current board positions include: BioStratum, Oncopeptides, Nordic Vision Clinics, RSPR, SwedenBIO and Targovax.

Gisela Schwab

Dr. Gisela M. Schwab, M.D., has been appointed Member of the Board of Directors of Nordic Nanovector ASA, effective as of March 12, 2015. She has served as Executive Vice President and Chief Medical Officer since January 2008 of Exelixis, Inc. She joined Exelixis in 2006 as Senior Vice President and Chief Medical Officer. From 2002 to 2006, she held the position of Senior Vice President and Chief Medical Officer at Abgenix, Inc., a human antibody-based drug development company. She also served as Vice President, Clinical Development at Abgenix from 1999 to 2001. Prior to working at Abgenix, from 1992 to 1999, she held positions of increasing responsibility at Amgen Inc., most recently as Director of Clinical Research and Haematology/OncologyTherapeutic Area Team Leader. From August 2011 to July 2014 Dr. Schwab has served as a member of the board of directors of Topotarget A/S, a publicly-held biopharmaceutical company. Since June 2012 she has served as a member of the board of directors of Cellerant Therapeutics, Inc. a privately held biopharmaceutical company. She received her Doctor of Medicine degree from the University of Heidelberg, trained at the University of Erlangen-Nuremberg and the National Cancer Institute, Bethesda Maryland, USA, and is board certified in internal medicine and hematology and oncology.

Joanna Horobin

Dr. Joanna C. Horobin, M.D., is a Non-Executive Director of the Company. Ms Horobin has comprehensive experience within the biopharmaceutical industry. She is currently Senior Vice President, Chief Medical Officer and a Member of the Leadership Team at Idera Pharmaceuticals, Inc. in Cambridge, MA, USA. Ms Horobin's current role includes the development and regulatory strategy as well as the execution of the clinical trial programme for the company's pipeline of novel oligonucleotides for the treatment of rare oncology and other indications. Prior to this position, she was CMO of Verastem, Inc. and CEO of Syndax Pharmaceuticals. Additionally, Ms Horobin has held several roles of increasing responsibility at global pharmaceutical companies such as Rhône Poulenc Rorer (now Sanofi) where she led the global launch of Taxotere® (docetaxel) in breast cancer and Campto/Camptosar® (CPT11) for colorectal cancer. Ms Horobin also led a successful joint venture with Chugai to launch Granocyte® (lenograstim) and played significant leadership roles in the approvals of several successful products.

Hilde Hermansen Steineger

Dr. Hilde Hermansen Steineger, Ph.D. has been Independent Director at NORDIC NANOVECTOR ASA since November 12, 2014. She is Chair of the Audit Committee and Member of Remuneration Committee. She is Head of Innovation Management at Pronova BioPharma ASA / BASF, a global leader in the research, development and manufacture of marine-originated omega-3 derived pharmaceutical products. Previously, Hilde Steineger was VP Investor Relations and Communications at Pronova BioPharma and prior to that she was Senior Associate with Neomed Management, an international investment firm focusing on the healthcare and life science industry. From 2004 to 2006, she worked as an independent advisor focusing on start-ups within the Life Science/Health Care sector, and before that, she was an equity analyst at Kreditkassen (now part of Nordea Markets) based in Oslo and Copenhagen (2001-2004). Hilde Steineger began her professional career at Nycomed Pharma, where she worked in the area of clinical research and international marketing from 1999 to 2001. Current board positions include: Strongbridge BioPharma and PCI Biotech. She holds a Bachelor of Science and a Ph.D. in Medical Biochemistry from the University of Oslo.